European Commission Approves Pfizer's PREVENAR 20 to Help Protect Infants and Children Against Pneumococcal Disease
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted Pfizer's PREVENAR 20 vaccine marketing authorization in the EU for protecting infants and children up to 18 years against pneumococcal disease.
March 13, 2024 | 8:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's PREVENAR 20 vaccine receives EU marketing authorization for pneumococcal disease prevention in those aged 6 weeks to under 18 years.
The approval of PREVENAR 20 by the European Commission is a significant milestone for Pfizer, potentially leading to increased vaccine sales in the European Union. This approval expands the vaccine's market, likely resulting in a positive short-term impact on Pfizer's stock price due to anticipated revenue growth from this new market segment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100